These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34800218)

  • 1. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
    Chang JI; Sinn DH; Cho H; Kim S; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2022 Sep; 67(9):4565-4573. PubMed ID: 34800218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA.
    Lee HA; Lee YS; Jung YK; Kim JH; Yim HJ; Yeon JE; Seo YS; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Gastroenterol Hepatol; 2023 May; 38(5):716-723. PubMed ID: 36681856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Li Z; Lei Z; Xia Y; Li J; Wang K; Zhang H; Wan X; Yang T; Zhou W; Wu M; Pawlik TM; Lau WY; Shen F
    JAMA Surg; 2018 Oct; 153(10):e182721. PubMed ID: 30073257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.
    Liu J; Shen H; Huang S; Lin J; Yan Z; Qian G; Lu Z; Wan X; Zhang F; Wang K; Zhang Y; Li J
    World J Surg Oncol; 2023 Feb; 21(1):42. PubMed ID: 36765340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis.
    Xu M; Zhou Z; Xu R; Zhang H; Lin N; Zhong Y
    World J Surg Oncol; 2019 Mar; 17(1):45. PubMed ID: 30823932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma.
    Huang S; Xia Y; Lei Z; Zou Q; Li J; Yang T; Wang K; Yan Z; Wan X; Shen F
    J Am Coll Surg; 2017 Mar; 224(3):283-293.e4. PubMed ID: 27923614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Prophylactic Anti-Hepatitis B Virus Therapy With Improved Long-term Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Therapy.
    Jang JW; Yoo SH; Nam HC; Jang BH; Sung Sung PS; Lee W; Kwon JH; Nam SW; Bae SH; Yoon SK; Choi JY
    Clin Infect Dis; 2020 Jul; 71(3):546-555. PubMed ID: 31504352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2023 Jan; 107():66-72. PubMed ID: 36347739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silymarin Synergizes with Antiviral Therapy in Hepatitis B Virus-Related Liver Cirrhosis: A Propensity Score Matching Multi-Institutional Study.
    Huang CH; Wu VC; Wang CL; Wu CL; Huang YT; Chang SH
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
    Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
    Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia.
    Kim TS; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    J Gastroenterol Hepatol; 2019 Nov; 34(11):2028-2035. PubMed ID: 31157456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
    Sohn W; Paik YH; Cho JY; Ahn JM; Choi GS; Kim JM; Kwon CH; Joh JW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    J Viral Hepat; 2015 Jun; 22(6):539-50. PubMed ID: 25377516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee EJ; Shin HJ; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    Cancer Epidemiol Biomarkers Prev; 2020 Apr; 29(4):832-837. PubMed ID: 31988073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma.
    Wei Q; Xu X; Ling Q; Zhou B; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2013 Jun; 12(3):251-5. PubMed ID: 23742769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels.
    Lee J; Sinn DH; Kim JH; Gwak GY; Kim HS; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    J Korean Med Sci; 2015 Nov; 30(11):1618-24. PubMed ID: 26539006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
    Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
    Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.
    Lee H; Jang S; Ahn SH; Kim BK
    Hepatol Int; 2022 Apr; 16(2):294-305. PubMed ID: 35322374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
    Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.